Alnylam Pharmaceuticals completes patient enrollment for Phase 3 trial of givosiran in acute hepatic porphyrias

pharmanewsdaily- August 22, 2018 0

Alnylam Pharmaceuticals has announced the completion of patient enrollment for its pivotal phase 3 trial, ENVISION, which evaluates the efficacy of givosiran in treating acute ... Read More